Benjamin Hohl - 27 Feb 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
29 Feb 2024, 17:27:02 UTC
Prior SEC filing
15 Feb 2024
Next SEC filing
29 Mar 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Benjamin Hohl
Filing notes and source

Key filing fact

Benjamin Hohl filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 29 Feb 2024.

Key facts

  • This page summarizes Benjamin Hohl's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 29 Feb 2024, 17:27.

Change

  • Previous filing in this sequence was filed on 15 Feb 2024.
  • Current net transaction value: -$47,103.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Options Exercise

Transaction value
$8,060
Shares
+3,250
Change %
Price
$2.48
Shares after
3,250
Date
27 Feb 2024
Ownership
Direct
Footnotes
F1
ELVN transaction

Common Stock

Sale

Transaction value
-$55,163
Shares
-3,250
Change %
-100%
Price
$16.97
Shares after
0
Date
27 Feb 2024
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
$0
Shares
-3,250
Change %
-1.3%
Price
$0.000000
Shares after
242,620
Date
27 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,250
Exercise price
$2.48
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $16.60 to $17.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .